Jul 2 |
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
|
May 21 |
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
|
May 7 |
Cognition Therapeutics GAAP EPS of -$0.27
|
May 7 |
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
|
Apr 29 |
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
|
Apr 22 |
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
|
Apr 18 |
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
|
Apr 2 |
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
|
Apr 1 |
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
|
Mar 27 |
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript
|